On September 11, 2026 Cellectis (the "Company") (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, reported that it will host a conference call and webcast on Monday, September 14, 2026 to provide a business update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call and Webcast Details :

September 14, 2026

English-language at 8:00 a.m. ET. / 2:00 p.m. CET
Webcast link:

View Source;tp_key=7d1d05c480

Phone number: +1 (800) 717 1738 or +1 (646) 307 1865

France Toll Free : +33 (800) 945 120

French-language at 9:00 a.m. ET. / 3:00 p.m. CET
Webcast link:

View Source;tp_key=2968b7b0ca

Phone number: +1 (800) 717 1738 or +1 (646) 307 1865

France Toll Free : +33 (800) 945 120

A replay will be available on the Company’s website following the event.

(Press release, Cellectis, SEP 11, 2026, https://www.cellectis.com/en/press/cellectis-to-host-conference-call-and-webcast-on-september-14-to-provide-a-business-update/ [SID1234670749])